How does PGEN's earnings trend look for 2025?

**Precigen's earnings trend for 2025 is poised for potential growth**, considering the following factors: 1. **Positive Pipeline Developments**: Precigen's focus on commercializing its lead asset, PRGN-2012, for recurrent respiratory papillomatosis is a significant driver for potential earnings growth. The FDA has granted priority review to the BLA for PRGN-2012, with a decision expected by August 2025. This timeline aligns with a potential commercial launch in 2025, assuming approval. 2. **Financial Positioning**: Despite increased research and development costs, Precigen ended 2024 with $97.9 million in cash, which extends its financial runway into 2026. This financial stability provides a solid foundation for potential earnings growth in 2025. 3. **Analyst Outlook**: Analysts maintain a positive outlook on Precigen, citing its promising pipeline and readiness for a prospective product launch. This sentiment suggests that earnings could exceed expectations if the PRGN-2012 asset is approved and launched successfully. 4. **Market Opportunity**: The target market for PRGN-2012, approximately 27,000 adult RRP patients in the US, represents a clear unmet medical need. If approved, PRGN-2012 could capture a significant market share, contributing to Precigen's earnings in 2025. In conclusion, while there are no available financial data for Q1 2025, the company's strategic advancements, financial positioning, and positive pipeline developments indicate a potential for earnings growth in 2025, contingent upon the FDA approval of PRGN-2012.